Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 11Dermatologic 5Sarcoma 3Genitourinary 3Other neoplasm 2Gastrointestinal 2Thoracic 1Lymphoid 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Precancerous Conditions 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Eflornithine × Gynecologic × Clear all
NCT00006079 2018-10-25

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

M.D. Anderson Cancer Center

Phase 2 Completed
150 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡